Abstract:This review highlights some of the research advances in anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects and in allergic skin disease that were reported in the Journal in 2008. Key epidemiologic observations include a rise in anaphylaxis in a population-based study and lower rates of peanut allergy in Israel, where infants consume peanut early compared with the United Kingdom, where dietary introduction is generally delayed. Advances in food allergy diagnosis include IgE epitope mapping that discloses the likelihood and severity of allergy; studies correlating likelihood of clinical reactivity on the basis of food-specific IgE to sesame, peanut, milk, and tree nuts; and an observation that a low baseline angiotensin-converting enzyme level may be associated with having pharyngeal edema during a reaction. Molecular, immunologic, and genetic studies are discerning pathways that are key in development of food allergy, identifying new modalities to interrupt mast cell degranulation, and elucidating risks associated with penicillin allergy. Regarding treatment, clinical studies show a majority of children with milk and egg allergy tolerate these proteins in modest amounts when they are extensively heated in baked goods, and studies show promise for oral immunotherapy to treat milk allergy and sublingual immunotherapy for honey bee venom hypersensitivity. The importance of skin barrier dysfunction has continued to be highlighted in the pathophysiology of atopic dermatitis (AD). Research has also continued to identify immunologic defects that contribute to the propensity of patients with AD to develop viral and bacterial infection. New therapeutic approaches to AD, urticaria, and angioedema have been reported including use of probiotics, biologics, vitamin D, and skin barrier creams.

Human vaccines and immunotherapeutics: News February 2024

Omalizumab (Xolair) for Food Allergy

News beyond our pages - June 2024

Omalizumab for the reduction of allergic reactions to foods: a narrative review

'Breakthrough' allergy drug: injection protects against severe food reactions

Biologics in Food Allergies: Emerging Therapies

Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: An observational study

The Incredible Adventure of Omalizumab

Omalizumab Implementation in Practice: Lessons Learned from the OUtMATCH Study

Peanut Oral Immunotherapy: a Current Perspective

Advances in targeted drugs for allergic diseases

Multiple Nahrungsmittelallergien: Omalizumab erhöht Reaktionsschwellen

Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)

The Future of Food Allergy Management: Advancements in Therapies

Human vaccines and immunotherapeutics: News September 2024

[Application of biologicals in patients with food allergies]

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2008

The Role of Biologics in the Treatment of Food Allergy

Human vaccines and immunotherapeutics: News January 2024

Human vaccines and immunotherapeutics: News December 2023

Prevention of Anaphylaxis Episodes in Idiopathic Anaphylaxis by Omalizumab